Overview
Empaveli is approved by the U.S. Food and Drug Administration (FDA) to reduce proteinuria (excess protein in the urine) in certain types of kidney disease, specifically C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). It is indicated for adults and children 12 years and older. To be eligible, individuals must have a confirmed diagnosis of C3G or IC-MPGN. Empaveli is also known by its drug name, pegcetacoplan.

Empaveli is a type of medication known as a complement inhibitor. It works by blocking part of the immune system called the complement system, which is thought to contribute to kidney inflammation and damage in people with C3G or IC-MPGN.

How do I take it?
Prescribing information states that Empaveli is taken by subcutaneous (under the skin) injection. For adults with C3G or IC-MPGN, it is usually given twice weekly. The drug can be administered using a commercially available pump or the Empaveli Injector. It should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Empaveli in people with C3G or primary IC-MPGN include infusion site reactions, fever, nasopharyngitis (nasal inflammation), flu, cough, and nausea.

Rare but serious side effects may include serious infections caused by encapsulated bacteria such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Even vaccinated individuals may still be at risk, so monitoring for signs of infection is important. Other serious risks include infusion-related reactions and interference with certain blood tests (e.g., artificially prolonged aPTT, a test used to measure blood clotting).

For more information about this treatment, visit:
Empaveli (Pegcetacoplan) Injection, for Subcutaneous Use — Apellis